Executive Director, DMPK

The Executive Director of DMPK is a senior strategic member of the Early Development Department and broader R&D Leadership team. This candidate will develop and implement DMPK strategies, and manage a multi-disciplinary DMPK group providing critical basic research and regulatory development support for products in discovery through late clinical development. The candidate will continue building a high-performing expertise function and team that will probe the DMPK behavior of all drugs across the platform and provide regulatory guidance and scientific stewardship for all development candidates. Responsibilities will include leading the design, execution, analysis, interpretation and communication of all non-clinical PK/PD and ADME studies relating to Anylam's siRNA therapeutic platforms. As the leader of DMPK, he/she will work closely with the research, preclinical, and clinical organizations across a spectrum of investigative research and highly regulated development studies. Therefore, this individual must be highly adept at building and managing relationships across various functions, and positioning results with a deep scientific understanding as to how the findings relate to early lead selection through late clinical development.

This position is onsite and will be primarily located in Cambridge, MA.

Key Responsibilities

* Create a compelling vision for DMPK and effectively communicating it throughout the company;

* Develop and executing superior DMPK strategies aligned with platform, programs and company goals to achieve successful world-wide registration of Alnylam drugs;

* Collaborate with Discovery Scientists and project leaders in establishing PK/ADME profiles during drug discovery to enable superior lead siRNA identification and drug candidate transition into development;

* Lead the DMPK team in the execution of all bioanalytical and preclinical

* PK/ADME studies using either in house resources or CROs;

* Either directly, or via members of his/her team, represent DMPK on a variety

* of interdisciplinary teams and all corporate governance forums;

* Ensure delivery of all reports and appropriate sections of regulatory documents to support INDs, NDAs and other world-wide regulatory dossiers;

* Become Alnylam's senior scientific expert and statesperson regarding siRNA therapeutics for DMPK and modeling, both internally and at external scientific conferences and regulatory agency meetings; and,

* Select and develop individuals with the talent necessary to achieve competitive superiority.

Qualifications

* Ph.D. in Pharmacokinetics, Drug Metabolism, or a related field is required.

* Minimum 15 years of industry experience demonstrating significant expertise, in-depth knowledge of DMPK science related to preclinical and clinical development and proven line-management leadership.

* This experience should come within a biotechnology and/or pharmaceutical environment and inside a complex research and development setting. Experience with oligonucleotide-based therapeutics is preferred or alternatively, the successful candidate will have experience with novel therapeutic modalities or multiple modalities, such as small molecules, biologics, antibody-drug conjugates, etc.

* The successful individual will have a track record in innovation and creativity, critical scientific thinking and analysis, with a deep level of curiosity and understanding of new technologies and cutting-edge approaches to address DMPK issues.

* Broad capabilities across pharmacokinetics, pharmacodynamics, ADME, modeling, and clinical pharmacology are essential to this individual's success.

* He/she must be able to demonstrate expert, world-class knowledge of pharmacokinetic and drug metabolism principles.

* Candidate should have a strong track record of independently authoring and providing regulatory guidance to team members on technical reports/ summaries, suitable for inclusion in registration dossiers (IB, IND/IMPD, NDA/BLA) and managing correspondence with regulatory authorities.

* The successful candidate will have strong interpersonal skills and a passion for science and the development of new, highly innovative technologies.

* In a growing and energized biotech environment such as Alnylam's, this individual must exhibit nimbleness, a willingness to step outside his or her comfort zone, be energized and motivated by robust debate, and a dedication to constant learning and personal development.

The Executive Director, DMPK must evidence the following qualities and characteristics:

* Flexible and adaptable style with a willing eagerness to take on challenges;

* Strong leadership, inspirational, and motivational capabilities;

* Entrepreneurial spirit with the willingness to take measured risks;

* Ability to work as a true team player and be effective in a collaborative culture;

* Personal versatility and flexibility as the program and DMPK teams evolve;

* A multifaceted individual who has the ability to articulate options and opinions

while engaging in intellectual debate,

* Abundant energy, and a sense of purpose that inspires others to take action;

* Ability to instill and quickly earn trust among colleagues and teams;

* Responsive and "quick-on-their-feet" when experiencing changes;

* Complex thinker who has the ability to articulate options for ambiguous situations

and the confidence to make decisions with authority and with full understanding

of potential outcomes;

* Ability to anticipate adverse scenarios and have contingency plans to address them;

* Excellent communication skills, both oral and written.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.